Trial Profile
A Retrospective study to determine the predictive factors for Pathological Complete Response associated with neoadjuvant trastuzumab-based treatment in patients with HER2 positive Breast Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary)
- Indications Breast cancer; HER2 positive breast cancer
- Focus Therapeutic Use
- 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record